Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA

Mélanie T. Mahoney; Hunter Brigman; Brian D Johnston; James R Johnson; Elizabeth B. Hirsch

doi:10.1016/j.ajic.2022.06.019

Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA

Mélanie T. Mahoney, Hunter Brigman, Brian D Johnston, James R Johnson, Elizabeth B. Hirsch

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Escherichia coli sequence type (ST) ST131, with its emergent resistance-associated H30Rx, H30R1, and C1-M27 clonal subsets, accounts for the greatest share of extraintestinal E. coli infections and most extended-spectrum β-lactamase (ESBL)-producing E. coli. Methods: We characterized and compared consecutive E. coli urine isolates from two geographically distinct medical centers in Minneapolis, Minnesota (n = 172) and Boston, Massachusetts (n = 143) for ESBL phenotype, CTX-M-type ESBL genes, phylogenetic groups, selected ST131 subclones, and 40 extraintestinal virulence genes. Results: Whereas the Boston vs. Minneapolis isolates had a similar prevalence of phylogenetic groups (mainly B2: 79% vs 73%), ST131 (34% vs 28%), H30 (28% vs 21%), and H30Rx (6% vs 5%), the emerging C1-M27 subclone occurred uniquely among Boston (6%) isolates. ESBL production was more prevalent among Boston isolates (15% vs 8%) and among ST131 isolates. Identified ESBL genes included bla_CTX-M-27 (Boston only) and bla_CTX-M-15. Ciprofloxacin resistance was ST131-associated and similarly prevalent across centers. Boston isolates had higher virulence gene scores. Conclusions: Despite numerous similarities to Minneapolis isolates, Boston ST131 isolates demonstrated more prevalent ESBL production, higher virulence gene scores, and, uniquely, the C1-M27 subclone and bla_CTX-M-27. Broader surveillance is needed to define the prevalence of ST131′s globally successful C1-M27 subclone across the U.S.

Original language	English (US)
Pages (from-to)	434-439
Number of pages	6
Journal	American journal of infection control
Volume	51
Issue number	4
DOIs	https://doi.org/10.1016/j.ajic.2022.06.019
State	Published - Apr 2023

Bibliographical note

Funding Information:
Funding/Support: This research was supported in part by Office of Research and Development, Department of Veteran Affairs , grant # 2I01CX000920-04 (J.R.J).

Funding Information:
Conflicts of interest: Elizabeth B. Hirsch has received research funding from Merck and advisory board honorarium from Melinta, MeMed, and Merck. James R. Johnson has had research grants and/or consultancies involving Achaogen, Allergan, Crucell/Janssen, Melinta, Merck, Shionogi, Syntiron, and Tetraphase, and has patent applications for tests to detect specific E. coli strains. All other authors declare no conflicts of interest.

Funding Information:
Funding/Support: This research was supported in part by Office of Research and Development, Department of Veteran Affairs, grant # 2I01CX000920-04 (J.R.J). Conflicts of interest: Elizabeth B. Hirsch has received research funding from Merck and advisory board honorarium from Melinta, MeMed, and Merck. James R. Johnson has had research grants and/or consultancies involving Achaogen, Allergan, Crucell/Janssen, Melinta, Merck, Shionogi, Syntiron, and Tetraphase, and has patent applications for tests to detect specific E. coli strains. All other authors declare no conflicts of interest.

Publisher Copyright:
© 2022 Association for Professionals in Infection Control and Epidemiology, Inc.

Keywords

E. coli
ESBL
ST131
Urinary tract infection
Virulence

PubMed: MeSH publication types

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Publisher link

10.1016/j.ajic.2022.06.019

Find It

Find It at U of M Libraries

Cite this

@article{f84018ff7bb44a70a83c5aaac9bd8ff4,

title = "Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA",

abstract = "Background: Escherichia coli sequence type (ST) ST131, with its emergent resistance-associated H30Rx, H30R1, and C1-M27 clonal subsets, accounts for the greatest share of extraintestinal E. coli infections and most extended-spectrum β-lactamase (ESBL)-producing E. coli. Methods: We characterized and compared consecutive E. coli urine isolates from two geographically distinct medical centers in Minneapolis, Minnesota (n = 172) and Boston, Massachusetts (n = 143) for ESBL phenotype, CTX-M-type ESBL genes, phylogenetic groups, selected ST131 subclones, and 40 extraintestinal virulence genes. Results: Whereas the Boston vs. Minneapolis isolates had a similar prevalence of phylogenetic groups (mainly B2: 79% vs 73%), ST131 (34% vs 28%), H30 (28% vs 21%), and H30Rx (6% vs 5%), the emerging C1-M27 subclone occurred uniquely among Boston (6%) isolates. ESBL production was more prevalent among Boston isolates (15% vs 8%) and among ST131 isolates. Identified ESBL genes included blaCTX-M-27 (Boston only) and blaCTX-M-15. Ciprofloxacin resistance was ST131-associated and similarly prevalent across centers. Boston isolates had higher virulence gene scores. Conclusions: Despite numerous similarities to Minneapolis isolates, Boston ST131 isolates demonstrated more prevalent ESBL production, higher virulence gene scores, and, uniquely, the C1-M27 subclone and blaCTX-M-27. Broader surveillance is needed to define the prevalence of ST131′s globally successful C1-M27 subclone across the U.S.",

keywords = "E. coli, ESBL, ST131, Urinary tract infection, Virulence",

author = "Mahoney, {M{\'e}lanie T.} and Hunter Brigman and Johnston, {Brian D} and Johnson, {James R} and Hirsch, {Elizabeth B.}",

note = "Funding Information: Funding/Support: This research was supported in part by Office of Research and Development, Department of Veteran Affairs , grant # 2I01CX000920-04 (J.R.J). Funding Information: Conflicts of interest: Elizabeth B. Hirsch has received research funding from Merck and advisory board honorarium from Melinta, MeMed, and Merck. James R. Johnson has had research grants and/or consultancies involving Achaogen, Allergan, Crucell/Janssen, Melinta, Merck, Shionogi, Syntiron, and Tetraphase, and has patent applications for tests to detect specific E. coli strains. All other authors declare no conflicts of interest. Funding Information: Funding/Support: This research was supported in part by Office of Research and Development, Department of Veteran Affairs, grant # 2I01CX000920-04 (J.R.J). Conflicts of interest: Elizabeth B. Hirsch has received research funding from Merck and advisory board honorarium from Melinta, MeMed, and Merck. James R. Johnson has had research grants and/or consultancies involving Achaogen, Allergan, Crucell/Janssen, Melinta, Merck, Shionogi, Syntiron, and Tetraphase, and has patent applications for tests to detect specific E. coli strains. All other authors declare no conflicts of interest. Publisher Copyright: {\textcopyright} 2022 Association for Professionals in Infection Control and Epidemiology, Inc.",

year = "2023",

month = apr,

doi = "10.1016/j.ajic.2022.06.019",

language = "English (US)",

volume = "51",

pages = "434--439",

journal = "American journal of infection control",

issn = "0196-6553",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA

AU - Mahoney, Mélanie T.

AU - Brigman, Hunter

AU - Johnston, Brian D

AU - Johnson, James R

AU - Hirsch, Elizabeth B.

N1 - Funding Information: Funding/Support: This research was supported in part by Office of Research and Development, Department of Veteran Affairs , grant # 2I01CX000920-04 (J.R.J). Funding Information: Conflicts of interest: Elizabeth B. Hirsch has received research funding from Merck and advisory board honorarium from Melinta, MeMed, and Merck. James R. Johnson has had research grants and/or consultancies involving Achaogen, Allergan, Crucell/Janssen, Melinta, Merck, Shionogi, Syntiron, and Tetraphase, and has patent applications for tests to detect specific E. coli strains. All other authors declare no conflicts of interest. Funding Information: Funding/Support: This research was supported in part by Office of Research and Development, Department of Veteran Affairs, grant # 2I01CX000920-04 (J.R.J). Conflicts of interest: Elizabeth B. Hirsch has received research funding from Merck and advisory board honorarium from Melinta, MeMed, and Merck. James R. Johnson has had research grants and/or consultancies involving Achaogen, Allergan, Crucell/Janssen, Melinta, Merck, Shionogi, Syntiron, and Tetraphase, and has patent applications for tests to detect specific E. coli strains. All other authors declare no conflicts of interest. Publisher Copyright: © 2022 Association for Professionals in Infection Control and Epidemiology, Inc.

PY - 2023/4

Y1 - 2023/4

N2 - Background: Escherichia coli sequence type (ST) ST131, with its emergent resistance-associated H30Rx, H30R1, and C1-M27 clonal subsets, accounts for the greatest share of extraintestinal E. coli infections and most extended-spectrum β-lactamase (ESBL)-producing E. coli. Methods: We characterized and compared consecutive E. coli urine isolates from two geographically distinct medical centers in Minneapolis, Minnesota (n = 172) and Boston, Massachusetts (n = 143) for ESBL phenotype, CTX-M-type ESBL genes, phylogenetic groups, selected ST131 subclones, and 40 extraintestinal virulence genes. Results: Whereas the Boston vs. Minneapolis isolates had a similar prevalence of phylogenetic groups (mainly B2: 79% vs 73%), ST131 (34% vs 28%), H30 (28% vs 21%), and H30Rx (6% vs 5%), the emerging C1-M27 subclone occurred uniquely among Boston (6%) isolates. ESBL production was more prevalent among Boston isolates (15% vs 8%) and among ST131 isolates. Identified ESBL genes included blaCTX-M-27 (Boston only) and blaCTX-M-15. Ciprofloxacin resistance was ST131-associated and similarly prevalent across centers. Boston isolates had higher virulence gene scores. Conclusions: Despite numerous similarities to Minneapolis isolates, Boston ST131 isolates demonstrated more prevalent ESBL production, higher virulence gene scores, and, uniquely, the C1-M27 subclone and blaCTX-M-27. Broader surveillance is needed to define the prevalence of ST131′s globally successful C1-M27 subclone across the U.S.

AB - Background: Escherichia coli sequence type (ST) ST131, with its emergent resistance-associated H30Rx, H30R1, and C1-M27 clonal subsets, accounts for the greatest share of extraintestinal E. coli infections and most extended-spectrum β-lactamase (ESBL)-producing E. coli. Methods: We characterized and compared consecutive E. coli urine isolates from two geographically distinct medical centers in Minneapolis, Minnesota (n = 172) and Boston, Massachusetts (n = 143) for ESBL phenotype, CTX-M-type ESBL genes, phylogenetic groups, selected ST131 subclones, and 40 extraintestinal virulence genes. Results: Whereas the Boston vs. Minneapolis isolates had a similar prevalence of phylogenetic groups (mainly B2: 79% vs 73%), ST131 (34% vs 28%), H30 (28% vs 21%), and H30Rx (6% vs 5%), the emerging C1-M27 subclone occurred uniquely among Boston (6%) isolates. ESBL production was more prevalent among Boston isolates (15% vs 8%) and among ST131 isolates. Identified ESBL genes included blaCTX-M-27 (Boston only) and blaCTX-M-15. Ciprofloxacin resistance was ST131-associated and similarly prevalent across centers. Boston isolates had higher virulence gene scores. Conclusions: Despite numerous similarities to Minneapolis isolates, Boston ST131 isolates demonstrated more prevalent ESBL production, higher virulence gene scores, and, uniquely, the C1-M27 subclone and blaCTX-M-27. Broader surveillance is needed to define the prevalence of ST131′s globally successful C1-M27 subclone across the U.S.

KW - E. coli

KW - ESBL

KW - ST131

KW - Urinary tract infection

KW - Virulence

UR - http://www.scopus.com/inward/record.url?scp=85135193575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135193575&partnerID=8YFLogxK

U2 - 10.1016/j.ajic.2022.06.019

DO - 10.1016/j.ajic.2022.06.019

M3 - Article

C2 - 35764181

AN - SCOPUS:85135193575

SN - 0196-6553

VL - 51

SP - 434

EP - 439

JO - American journal of infection control

JF - American journal of infection control

IS - 4

ER -

Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USA

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this